At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
SK&F-105517-D 10 mg capsule +4 moredrug
Likely dose
SK&F-105517-D 10 mg capsulefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Safety and Tolerability of SK&F-105517-D in Patients With Chronic Heart Failure- An Open-label Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SK&F-105517-D in Patients With Chronic Heart Failure (Phase I/II Study)
In Brief
A Phase 1 clinical trial evaluating SK&F-105517-D 10 mg capsule, Carvedilol-immediate release (IR) 2.5 mg tablet, and 3 other interventions for Heart Failure, Congestive. Completed, enrolled 41 participants across 23 sites.
Detailed Summary
The primary objective of this study is to evaluate the safety and tolerability of SK\&F-105517-D in japanese patients with chronic heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Congestive
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartAug 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedAug 27, 2008
Enrollment StartAug 28, 2008
Primary CompletionAug 21, 2009
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 17.8 years ago
Interventions
SK&F-105517-D 10 mg capsuledrug
1 capsule once a day
Carvedilol-immediate release (IR) 2.5 mg tabletdrug
1 or 2 tablet(s) twice a day
SK&F-105517-D 20 mg capsuledrug
1 capsule once a day
SK&F-105517-D 40 mg capsuledrug
1 or 2 capsule(s) once a day
Carvedilol-IR 10 mg tabletdrug
1 tablet twice a day